Correlation of nm23-H1 gene expression with clinical outcome in patients with advanced breast cancer

In Vivo

Volumn 21, Issue 3, 2007, Pages 519-522

  Sgouros, Joseph ^a,e   Galani, Eleni ^a,b   Gonos, Efstathios ^c   Moutsatsou, Paraskeui ^a   Belechri, Maria ^d   Skarlos, Demosthenes ^b   Dionyssiou Asteriou, Amalia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Errikos Dinan Hospital   (Greece)

^c INSTITUTE OF BIOLOGY   (Greece)

^d CASTLE HILL HOSPITAL   (United Kingdom)

^e NONE   (United Kingdom)

Author keywords

Advanced breast cancer; Nm23 H1 gene; Prognostic factor; RT PCR

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; EPIRUBICIN; ESTROGEN RECEPTOR; NUCLEOSIDE DIPHOSPHATE KINASE A; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; PROGNOSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

EID: 34250216667     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA and Sobel ME: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 80: 200-204, 1988.
2. Bevilacqua G, Sobel ME, Liotta LA and Steeg PS: Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 49: 5185-5190, 1989.
3. Hennessy C, Henry JA, May FEB, Westley BR, Angus B and Lennerd TWJ: Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. J Natl Cancer Inst 83: 281-285, 1991.
4. Royds JA, Stephenson TJ, Rees RC, Shorthouse AJ and Silcocks PB: Nm23 protein expression in ductal in situ and invasive human breast carcinoma. J Natl Cancer Inst 85: 727-731, 1993.
5. Srivatsa PJ, Cliby WA, Keeney GL, Dodson MK, Suman VJ, Roche PC and Podratz KC: Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma. Gynecol Oncol 60: 363-372, 1996.
6. Scambia G, Ferrandina G, Marone M, Benedetti Panici P, Giannitelli C, Piantelli M, Leone A and Mancuso S: nm23 in ovarian cancer: correlation with clinical outcome and other clinicopathologic and biochemical prognostic parameters. J Clin Oncol 14: 334-342, 1996.
7. Nakayama H, Yasui W, Yokozaki H and Tahara E: Reduced expression of nm23 is associated with metastasis of human gastric carcinomas. Jpn J Cancer Res 84: 184-190, 1993.
8. Kumar Dhar D, Kubota H, Tabara H, Kotoh T, Monden N, Igarashi M, Kohno H and Nagasue N: nm23 in the primary and metastatic sites of gastric carcinoma. Relation to AFP-producing carcinoma. Oncology 56: 122-128, 1999.
9. Galani E, Sgouros J, Petropoulou C, Janinis J, Aravantinos G, Dionyssiou-Asteriou A, Skarlos D and Gonos E: Correlation of MDR1, nm23-H1 and H Sema E gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients. Anticancer Res 22: 2275-2280, 2002.
10. Wood WC, Muss HB, Solin LJ and Olopade OI: Malignant tumors of the breast. In: Cancer. Principles and Practice of Oncology. DeVita VT Jr, Hellman S, Rosenberg SA (eds.). Philadelphia, Lippincott Williams and Wilkins, pp. 1415-1477, 2005.
11. Kaplan E and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
12. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Horschowski N, Lavaut MN and Allasia C: Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays. J Pathol 184: 401-407, 1998.
13. Russell RL, Geisinger KR, Mehta RR, White WL, Shelton B and Kute TE: nm23-Relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts and lymph node negative breast carcinoma patients. Cancer 79: 1158-1165, 1997.
14. Steeg PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3: 55-63, 2003.
15. Goodal RJ, Dawkins HJ, Robbins PD, Hahnel E, Sarna M, Hahnel R, Papadimitriou JM, Harvey JM and Sterrett GF: Evaluation of the expression levels of nm23-H1 mRNA in primary breast cancer, benign breast disease, axillary lymph nodes and normal breast tissue. Pathology 26: 423-428, 1994.
16. Stark AM, Tongers K, Maass N, Mehdorn HM and Held-Feindt J: Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol 131: 191-198, 2005.